Detecting protein variants by mass spectrometry: a comprehensive study in cancer cell-lines

Abstract

BackgroundOnco-proteogenomics aims to understand how changes in a cancer’s genome influences its proteome. One challenge in integrating these molecular data is the identification of aberrant protein products from mass-spectrometry (MS) datasets, as traditional proteomic analyses only identify proteins from a reference sequence database.MethodsWe established proteomic workflows to detect peptide variants within MS datasets. We used a combination of publicly available population variants (dbSNP and UniProt) and somatic variations in cancer (COSMIC) along with sample-specific genomic and transcriptomic data to examine proteome variation within and across 59 cancer cell-lines.ResultsWe developed a set of recommendations for the detection of variants using three search algorithms, a split target-decoy approach for FDR estimation, and multiple post-search filters. We examined 7.3 million unique variant tryptic peptides not found within any reference proteome and identified 4771 mutations corresponding to somatic and germline deviations from reference proteomes in 2200 genes among the NCI60 cell-line proteomes.ConclusionsWe discuss in detail the technical and computational challenges in identifying variant peptides by MS and show that uncovering these variants allows the identification of druggable mutations within important cancer genes.Electronic supplementary materialThe online version of this article (doi:10.1186/s13073-017-0454-9) contains supplementary material, which is available to authorized users.

Precision De Novo Peptide Sequencing Using Mirror Proteases of Ac-LysargiNase and Trypsin for Large-scale Proteomics

“…Mirror Protease Strategy for Precision De Novo Sequencing on Long Peptides-Previous studies have reported that the ion coverage negatively correlated with the length of peptides, which indicates a challenge to sequence long peptides (11,44,45). We investigated the impact of peptide length on de novo sequencing.…”

Origins and clinical relevance of proteoforms in pediatric malignancies

“…Top-down mass spectrometry allows for the determination of amino acid sequences and their PTMs without first digesting proteins into peptides. This provides more precise compositional information and adds molecular details which are typically lost when proteins are first digested into peptides as done in bottom-up proteomics [22,159] (Figure 3 (a-b)). Mass spectrometry of complete proteins is the most optimal method to detect de novo proteoforms with complex PTM patterns [6].…”

“…It is essential to understand the connection between genomic sequence and proteomic activity when trying to develop effective treatments [129,168,169]. Furthermore, this sample specific approach utilizing custom search databases has shown lower false-positive and false-negative rates making mass spectrometry data increasingly reliable [159].…”

Connecting Proteomics to Next‐Generation Sequencing: Proteogenomics and Its Current Applications in Biology

“…Likewise, Alfaro et al. combined publicly available variants (dbSNP and UniProt) and somatic variations in cancer (COSMIC); along with sample‐specific genomic and transcriptomic data to examine proteome variation in 59 NCI60 cancer cell‐lines, resulting in the identification of 7.3 million novel variant peptides and 4771 mutations . In a separate study, Zhang et al.…”